stock downgrade
BTIG Downgrades Oncocyte to Neutral Following News of CEO Departure
In an announcement late Wednesday, the company said Ronnie Andrews had stepped down, marking the firm's third major executive to depart in recent months.
Canaccord Downgrades T2 Biosystems to Hold
The investment bank cited a soft Q3 outlook, slower-than-expected pipeline progress, and capital and liquidity concerns raised in the company's preliminary quarterly results.
Evercore ISI Downgrades PerkinElmer Shares to In Line
The bank previously had an Outperform Rating on PerkinElmer, and it also lowered its price target for the firm's stock to $150 per share from $175 per share.
William Blair Downgrades Lucira Health to Market Perform
As a result of the downgrade, the bank also significantly reduced revenue and volume estimates for 2021 and 2022.
Roche to Acquire GenMark Diagnostics for $1.8B
Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.
Feb 1, 2021
Oppenheimer Downgrades Invitae to Perform Rating
Nov 24, 2020
BTIG Downgrades Fulgent Genetics from Buy to Neutral
Oct 14, 2020
JP Morgan Rates Invitae Neutral
Jul 16, 2019
Qiagen Stock Downgraded to 'In Line' by Evercore ISI
Jul 9, 2019
Cowen Downgrades Myriad Genetics' Stock
Oct 25, 2018
LabCorp Downgraded by Canaccord Genuity
May 24, 2018
Vermillion Downgraded by Canaccord to Hold Rating
Dec 13, 2017